Clinical trial
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
NCT04840667 is registered in ClinicalTrials.gov with Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
- Lead sponsor
- Shire
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 28, 2021
- Completion date
- December 16, 2022
- Enrollment
- 17 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.